Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients

被引:6
|
作者
Hatairaktham, Suneerat [1 ]
Masaratana, Patarabutr [1 ]
Hantaweepant, Chattree [2 ]
Srisawat, Chatchawan [1 ]
Sirivatanauksorn, Vorapan [1 ]
Siritanaratkul, Noppadol [2 ]
Panichkul, Narumol [1 ]
Kalpravidh, Ruchaneekorn W. [1 ]
机构
[1] Mahidol Univ, Fac Med, Dept Biochem, Siriraj Hosp, 2 Wanglang Rd, Bangkok 10700, Thailand
[2] Mahidol Univ, Fac Med, Div Hematol, Dept Med,Siriraj Hosp, Bangkok, Thailand
关键词
Curcumin; Curcuminoids; Inflammation; Iron overload; Oxidative stress; Thalassemia; TRANSFERRIN-BOUND IRON; PEPTIDE HEPCIDIN; MAJOR PATIENTS; DEFERIPRONE; CYTOKINES; BENEFITS; REMOVAL; GENE;
D O I
10.1007/s00277-020-04379-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Curcuminoids, polyphenol compounds in turmeric, possess several pharmacological properties including antioxidant, iron-chelating, and anti-inflammatory activities. Effects of curcuminoids in thalassemia patients have been explored in a limited number of studies using different doses of curcuminoids. The present study aims to evaluate the effects of 24-week curcuminoids supplementation at the dosage of 500 and 1000 mg/day on iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfused beta-thalassemia/Hb E patients. In general, both curcuminoids dosages significantly lowered the levels of oxidative stress, hypercoagulability, and inflammatory markers in the patients. In contrast, reductions in iron parameter levels were more remarkable in the 1000 mg/day group. Subgroup analysis revealed that a marker of hypercoagulability was significantly decreased only in patients with baseline ferritin <= 1000 ng/ml independently of curcuminoids dosage. Moreover, the alleviation of iron loading parameters was more remarkable in patients with baseline ferritin > 1000 ng/ml who receive 1000 mg/day curcuminoids. On the other hand, the responses of oxidative stress markers were higher with 500 mg/day curcuminoids regardless of baseline ferritin levels. Our study suggests that baseline ferritin levels should be considered in the supplementation of curcuminoids and the appropriate curcuminoids dosage might differ according to the required therapeutic effect. Thai Clinical Trials Registry (TCTR): TCTR20200731003; July 31, 2020 "retrospectively registered"
引用
收藏
页码:891 / 901
页数:11
相关论文
共 50 条
  • [31] Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
    Bou-Fakhredin, Rayan
    Bazarbachi, Abdul-Hamid
    Chaya, Bachar
    Sleiman, Joseph
    Cappellini, Maria Domenica
    Taher, Ali T.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (12)
  • [32] Molecular Understanding of Non-Transfusion-Dependent Thalassemia Associated with Hemoglobin E-β-Thalassemia in Northeast Thailand
    Yamsri, Supawadee
    Pakdee, Naruwat
    Fucharoen, Goonnapa
    Sanchaisuriya, Kanokwan
    Fucharoen, Supan
    ACTA HAEMATOLOGICA, 2016, 136 (04) : 233 - 239
  • [33] Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia INTRODUCTION
    Taher, Ali T.
    Cappellini, Maria D.
    Musallam, Khaled M.
    BLOOD REVIEWS, 2012, 26 : S1 - S2
  • [34] Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
    Taher, Ali T.
    Porter, John B.
    Viprakasit, Vip
    Kattamis, Antonis
    Chuncharunee, Suporn
    Sutcharitchan, Pranee
    Siritanaratkul, Noppadol
    Origa, Raffaella
    Karakas, Zeynep
    Habr, Dany
    Zhu, Zewen
    Cappellini, M. Domenica
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (06) : 521 - 526
  • [35] Prevalence of abnormal glucose homeostasis in Chinese patients with non-transfusion-dependent thalassemia
    Luo, Yunchen
    Bajoria, Rekha
    Lai, Yongrong
    Pan, Hongfei
    Li, Qiaochuan
    Zhang, Zhongming
    Yang, Pijian
    Chatterjee, Ratna
    Liang, Yuzhen
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 457 - 468
  • [36] Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
    Taher, Ali T.
    Porter, John B.
    Viprakasit, Vip
    Kattamis, Antonis
    Chuncharunee, Suporn
    Sutcharitchan, Pranee
    Siritanaratkul, Noppadol
    Galanello, Renzo
    Karakas, Zeynep
    Lawniczek, Tomasz
    Habr, Dany
    Ros, Jacqueline
    Zhu, Zewen
    Cappellini, M. Domenica
    ANNALS OF HEMATOLOGY, 2013, 92 (11) : 1485 - 1493
  • [37] Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
    Ali T. Taher
    John B. Porter
    Vip Viprakasit
    Antonis Kattamis
    Suporn Chuncharunee
    Pranee Sutcharitchan
    Noppadol Siritanaratkul
    Renzo Galanello
    Zeynep Karakas
    Tomasz Lawniczek
    Dany Habr
    Jacqueline Ros
    Zewen Zhu
    M. Domenica Cappellini
    Annals of Hematology, 2013, 92 : 1485 - 1493
  • [38] Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
    Porter, John B.
    Cappellini, Maria Domenica
    Kattamis, Antonis
    Viprakasit, Vip
    Musallam, Khaled M.
    Zhu, Zewen
    Taher, Ali T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (02) : 288 - 299
  • [39] CHANGES IN ALTERNATIVE IRON OVERLOAD PARAMETERS FOLLOWING 1 YEAR OF DEFERASIROX THERAPY IN PATIENTS WITH NON-TRANSFUSION-DEPENDENT THALASSEMIA: A LONGITUDINAL ANALYSIS FROM THE THALASSA STUDY
    Porter, J. B.
    Cappellini, M. D.
    Kattamis, A.
    Viprakasit, V.
    Musallam, K. M.
    Zhu, Z.
    Taher, A. T.
    HAEMATOLOGICA, 2014, 99 : 441 - 442
  • [40] EFFECT OF CHELATION ON CARDIAC IRON OVERLOAD IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA
    Pines, Morgan
    Sheth, Sujit
    Kleinert, Dorothy
    PEDIATRIC BLOOD & CANCER, 2022, 69